Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115095
Chunk: 255

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 255
---
 |

| • |     | There were no meaningful differences observed in physical examinations, vital signs, or laboratory parameters between treatment groups. |

The data from the primary endpoint analyses is graphically presented below. Summary tables are also provided for primary and secondary endpoints. 163

Mean Change From Baseline in NPRS Average Pain Score (Standard Error) in the Affected Leg (ITT Population) SP-102vs Placebo Weeks 1,2,3,4: p = 0.002, 0.005, 0.003, 0.003. Overall treatment Effect (Mean SP-102vs Placebo difference): Diff = -0.52,SE= 0.163, p = 0.002. Error Bars: 95% Confidence Limits. Primary and Secondary Outcomes: NPRS Average Leg Pain In Affected Leg, ODI Total Score, Mean Daily NPRS (worst, current, and lower back), PainDetect, BPI-SF(Change from Baseline to Four Weeks; ITT Population)

| Endpoint                                                          |     | SP-102           
 N=202            
 Mean Change from 
 Baseline(1)      |     | Placebo          
 N=199            
 Mean Change from 
 Baseline         |     | LSM (SE)     |     | 95% CI       |     | P-value |
| NPRS Average Pain Score in the Affected Leg (primary endpoint)(2) |     | -1.81(1.896)     |     | -1.29(1.814)     |     | -0.55(0.187) |     | -0.92, -0.18 |     |   0.003 |
| ODI total score (key secondary endpoint)(3)                       |     | -8.88(14.684)    |     | -5.48(13.083)    |     | -3.38(1.388) |     | -6.11, -0.65 |     |   0.015 |
| Worst pain in affected leg at Week Four(2)                        |     | -1.88(2.014)     |     | -1.33(1.946)     |     | -0.57(0.198) |     | -0.96, -0.18 |     |   0.004 |
| Worst pain in affected leg over Four Weeks